Related references
Note: Only part of the references are listed.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Junfei Zhao et al.
NATURE MEDICINE (2019)
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
Gaia Griguolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
305OOverall survival (OS) in KATE2, a phase II study of programmed death ligand 1 (PD-L1) inhibitor atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
L A Emens et al.
ANNALS OF ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Tiziana Triulzi et al.
BRITISH JOURNAL OF CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
G. Bianchini et al.
ANNALS OF ONCOLOGY (2015)
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
Philipp Mueller et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
The immune system and response to HER2-targeted treatment in breast cancer
Giampaolo Bianchini et al.
LANCET ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Share Paper
